Cargando…

Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, and it usually occurs following chronic liver disease. Although some progress has been made in the treatment of HCC, the prognosis of patients with advanced HCC is not optimistic, mainly because of the inevitable develop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Lei, Li, Luan, Liu, Yongzhuang, Zhan, Meixiao, Lu, Ligong, Yuan, Shengtao, Liu, Yanyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987615/ https://www.ncbi.nlm.nih.gov/pubmed/36891274 http://dx.doi.org/10.3389/fphar.2023.1097277

Ejemplares similares

Erratum: Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
por: Frontiers Production Office,
Publicado: (2023)

Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway
por: Hou, Xiaoying, et al.
Publicado: (2018)

Artesunate Regulates Neurite Outgrowth Inhibitor Protein B Receptor to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells
por: He, Wubin, et al.
Publicado: (2021)

A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
por: Guan, Renguo, et al.
Publicado: (2022)

Uncovering the Mechanisms of Cryptotanshinone as a Therapeutic Agent Against Hepatocellular Carcinoma
por: Luo, Yi, et al.
Publicado: (2020)

Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma
por: Berretta, Massimiliano, et al.
Publicado: (2016)

Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression
por: Wang, Hao, et al.
Publicado: (2020)

Knockdown of TANK-Binding Kinase 1 Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular-Targeted Drugs
por: Du, Fengxia, et al.
Publicado: (2022)

Sepiapterin reductase promotes hepatocellular carcinoma progression via FoxO3a/Bim signaling in a nonenzymatic manner
por: Wu, Yao, et al.
Publicado: (2020)

Novel Mechanism for an Old Drug: Phenazopyridine is a Kinase Inhibitor Affecting Autophagy and Cellular Differentiation
por: Preynat-Seauve, Olivier, et al.
Publicado: (2021)

Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells
por: Hou, Xiaoying, et al.
Publicado: (2022)

miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting TXNRD1
por: Hua, Shengni, et al.
Publicado: (2019)

Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma
por: Xia, Zhong-Kun, et al.
Publicado: (2021)

Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms
por: Kiełbowski, Kajetan, et al.
Publicado: (2023)

Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis
por: Paech, Franziska, et al.
Publicado: (2017)

Identification of hub genes in hepatocellular carcinoma using integrated bioinformatic analysis
por: Hua, Shengni, et al.
Publicado: (2020)

Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights
por: Tian, Xinchen, et al.
Publicado: (2022)

Rapid Determination of 9 Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma in Human Plasma by QuEChERS-UPLC-MS/MS
por: Jiang, Wen, et al.
Publicado: (2022)

Mechanisms of tumor-associated macrophages affecting the progression of hepatocellular carcinoma
por: Yuan, Yi, et al.
Publicado: (2023)

Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma
por: Huang, Jingjun, et al.
Publicado: (2021)

Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity
por: Chen, Xiaojie, et al.
Publicado: (2022)

Computational and In Vitro Analysis of Plumbagin’s Molecular Mechanism for the Treatment of Hepatocellular Carcinoma
por: Wei, Yanfei, et al.
Publicado: (2021)

Sepiapterin reductase: Characteristics and role in diseases
por: Wu, Yao, et al.
Publicado: (2020)

The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma
por: Zhou, Zhimei, et al.
Publicado: (2021)

Metal-organic frameworks for hepatocellular carcinoma therapy and mechanism
por: Feng, Yingqi, et al.
Publicado: (2022)

Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data
por: Liu, Shaoqing, et al.
Publicado: (2021)

Ubiquitin-proteasome system-based signature to predict the prognosis and drug sensitivity of hepatocellular carcinoma
por: Zhang, Jianxiang, et al.
Publicado: (2023)

Study on the mechanism of action of Scutellaria barbata on hepatocellular carcinoma based on network pharmacology and bioinformatics
por: Yang, An-Yin, et al.
Publicado: (2023)

SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma
por: Xu, Hongfa, et al.
Publicado: (2020)

Inflammation Resolution and the Induction of Granulocyte Apoptosis by Cyclin-Dependent Kinase Inhibitor Drugs
por: Cartwright, Jennifer A., et al.
Publicado: (2019)

Advances in RIPK1 kinase inhibitors
por: Chen, Lu, et al.
Publicado: (2022)

Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp
por: Zhao, Tingting, et al.
Publicado: (2022)

Role of ferroptosis and its non-coding RNA regulation in hepatocellular carcinoma
por: Yang, Lei, et al.
Publicado: (2023)

A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model
por: Wei, Yuhua, et al.
Publicado: (2022)

The Kinase Specificity of Protein Kinase Inhibitor Peptide
por: Chen, Yao, et al.
Publicado: (2021)

Immunotherapies for advanced hepatocellular carcinoma
por: Sun, Li-Yang, et al.
Publicado: (2023)

Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis
por: Liu, Zhi-Yong, et al.
Publicado: (2022)

The Mechanisms of Current Platinum Anticancer Drug Resistance in the Glioma
por: Lu, Enzhou, et al.
Publicado: (2022)

Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score
por: Li, Yongjiang, et al.
Publicado: (2022)

CXCL12 and IL7R as Novel Therapeutic Targets for Liver Hepatocellular Carcinoma Are Correlated With Somatic Mutations and the Tumor Immunological Microenvironment
por: He, Ke, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ejjakbv5a3kvcc20di86q0m1bc